TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ).
AstraZeneca Pharma India Limited has announced that it received approval from the Central Drugs Standard Control Organisation to import and market Trastuzumab Deruxtecan (Enhertu) for a new indication in India. This approval allows the company to provide treatment for adult patients with unresectable or metastatic HER2-positive solid tumors who have previously undergone systemic treatment and lack satisfactory alternative options, potentially enhancing the company’s market presence in oncology.
More about AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the development and distribution of prescription medicines. The company is known for its innovative products in various therapeutic areas, including oncology, cardiovascular, renal, and metabolism.
Average Trading Volume: 1,322
Technical Sentiment Signal: Strong Buy
Current Market Cap: 230.5B INR
For a thorough assessment of ASTRAZEN stock, go to TipRanks’ Stock Analysis page.